Impact of the COVID-19 Pandemic on a Cancer Fast-Track Programme

Author:

Martínez M. T.1,Moragon S.1ORCID,Ortega-Morillo B.1,Montón-Bueno J.1,Simon S.1,Roselló S.123,Insa A.1,Viala A.1,Navarro J.45,Sanmartín A.4,Fluixá C.6,Julve A.7,Soriano D.7,Buch E.8ORCID,Peña A.9,Franco J.10,Martínez-Jabaloyas J.11,Marco J.12,Forner M. J.13,Cano A.14,Silvestre A.15,Teruel A16,Bermejo B.123,Cervantes A.123,Chirivella Gonzalez I.1

Affiliation:

1. Department of Medical Oncology Department, Hospital Clínico Universitario, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain

2. Department of Medical Oncology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain

3. Instituto de Salud Carlos III, CIBERONC, Madrid, Spain

4. Management Department, Hospital Clinico Universitario de Valencia, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain

5. CIBERESP (CIBER de Epidemiología y Salud Pública), Centro Nacional de Epidemiología Del Instituto de Salud Carlos III, Madrid, Spain

6. Alfahuir Primare Care Center, Valencia, Spain

7. Department of Radiodiagnosis, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain

8. Department of Surgery, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain

9. Department of Medicine Digestive, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain

10. Department of Pneumology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain

11. Department of Urology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain

12. Department of Otolaryngology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain

13. Department of Internal Medicine, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain

14. Department of Gynaecology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain

15. Department of Traumatology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain

16. Department of Haematology, INCLIVA Biomedical Research Institute, University of Valencia, Valencia, Spain

Abstract

Introduction The COVID-19 pandemic has disrupted many aspects of clinical practice in oncology, particularly regarding early cancer diagnosis, sparking public health concerns that possible delays could increase the proportion of patients diagnosed at advanced stages. In 2009, a cancer fast-track program (CFP) was implemented at the Clinico-Malvarrosa Health Department in Valencia, Spain with the aim of shortening waiting times between suspected cancer symptoms, diagnosis and therapy initiation. Objectives The study aimed to explore the effects of the COVID-19 pandemic on our cancer diagnosis fast-track program. Methods The program workflow (patients included and time periods) was analysed from the beginning of the state of alarm on March 16th, 2020 until March 15th, 2021. Data was compared with data from the same period of time from the year before (2019). Results During the pandemic year, 975 suspected cancer cases were submitted to the CFP. The number of submissions only decreased during times of highest COVID-19 incidence and stricter lockdown, and overall, referrals were slightly higher than in the previous 2 years. Cancer diagnosis was confirmed in 197 (24.1%) cases, among which 33% were urological, 23% breast, 16% gastrointestinal and 9% lung cancer. The median time from referral to specialist appointment was 13 days and diagnosis was reached at a median of 18 days. In confirmed cancer cases, treatment was started at around 30 days from time of diagnosis. In total, 61% of cancer disease was detected at early stage, 20% at locally advanced stage, and 19% at advanced stage, displaying time frames and case proportions similar to pre-pandemic years. Conclusions Our program has been able to maintain normal flow and efficacy despite the challenges of the current pandemic, and has proven a reliable tool to help primary care physicians referring suspected cancer patients.

Publisher

SAGE Publications

Subject

Oncology,Hematology,General Medicine

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3